| 07.08.24 | Lilly pays $3.2B for Morphic to rival Takeda; HilleVax stock sinks after norovirus fail

Click here to subscribe to Fiercebiotech.com

4 months ago

Html
Text


A message from McKesson Compile

Today’s Big News

Jul 8, 2024

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster

Takeda spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants

Roche stops pivotal TIGIT trial after Keytruda lands knockout blow at first attempt

'Galvanized' by early data, British biotech Myricx secures $114M series A to take ADCs into clinic

Fierce Biotech Summit

September 30- October 1, 2024 | Boston, MA

Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights.

Grab your pass today!

Featured

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster

By Nick Paul Taylor

Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio.

Takeda spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants

By James Waldron

HilleVax's stock took a nosedive after the vaccine biotech’s sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis.

Roche stops pivotal TIGIT trial after Keytruda lands knockout blow at first attempt

By Nick Paul Taylor

Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.

'Galvanized' by early data, British biotech Myricx secures $114M series A to take ADCs into clinic

By James Waldron

When it comes to the red-hot antibody-drug conjugate space, Big Pharmas have tended to head to China to build up their pipelines. But U.K.-based Myricx Bio has caught the eye of a crop of major investors courtesy of its unique science

Alcon inks $466M deal for Belkin Vision's automated laser therapy for glaucoma

By Conor Hale

The deal includes an upfront transfer of $81 million, including about $65 million in cash—plus the opportunity for up to $385 million more in sales-based milestone payments.

With Boehringer ruling, industry extends legal losing streak against Medicare price negotiations

By Eric Sagonowsky

Boehringer Ingelheim joins AstraZeneca, J&J and Bristol Myers Squibb in having a case challenging Medicare price negotiations fail to bear fruit. Lawsuits from Novo Nordisk, Merck and Novartis are still pending.

Federal judge blocks HHS rule protecting LGBTQ+ patients from discrimination

By Anastassia Gliadkovskaya

In a preliminary injunction, the judge cited the Supreme Court's recent overturning of Chevron deference, which weakened the power of federal agencies. The judge also said HHS was wrong to rely on a previous SCOTUS ruling in applying protections on the basis of sex to gender identity.

Novo’s Ozempic, Wegovy linked to potential eye problem? Not so fast, analysts say

By Angus Liu

Novo Nordisk’s popular GLP-1 analog semaglutide may be linked to a vision-loss disorder, a study suggests. But one team of analysts cautioned against reading too much into the analysis.

Fierce podcasts

Don’t miss an episode

The best biopharma M&A deals

In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years.

Designing with neurodiversity in mind

A closer look at 'friend-shoring' and the drug shortage challenge


A message from Digital Pharma East

Resources

Whitepaper

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing

In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.

The “Best Practice Organization” & Its Importance for Success in Today’s Biopharma Industry

In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers.

Sponsored by: Blue Matter, strategic consultants in the life sciences